Eyeworld

I MAY 2020 | EYEWORLD | 57 0.02%/latanoprost 0.005%, netarsudil alone, and latanoprost alone. IOP reductions with the fixed-dose combination ranged from 7.2–9.2 mm Hg (31–36%) from baseline—reductions up to 3 mm Hg greater than with the individual components. Furthermore, efficacy through 12 months of dosing were consistent with 3-month results. 5 Real-world experience has also been re- ported. Dr. Serle cited a retrospective review of netarsudil in 172 eyes of 108 patients that con- firmed that netarsudil is additive to other med- ications used to treat glaucoma. 6 "This study suggests netarsudil is efficacious early in the disease when patients are presumably receiving fewer medications as well as later in the disease when patients tend to be on more medications to control intraocular pressure," she said. Pooled data from the APOLLO and LUNAR trials comparing once-daily latanopro- stene bunod with twice-daily timolol 0.5% in 831 patients with open angle glaucoma demon- strated greater (p<0.001) IOP lowering with latanoprostene bunod at all nine measured time points, with mean IOP reductions of 7.5–9.1 mm Hg from baseline through 3 months of treatment. 1 In VOYAGER, latanoprostene bunod was superior to latanoprost with mean IOP reductions of about 9 mm Hg at 4 weeks. 2 The pooled data including 1,621 patients from ROCKET-1, -2, and -4 showed that IOP lowering with netarsudil 0.02% once daily (17.5–19.5 mm Hg) was comparable to that with timolol 0.5% twice daily (17.6–18.4 mm Hg) at nine time points through 3 months of treatment. 3,4 The MERCURY trials had three arms test- ing the fixed-dosed combination of netarsudil continued on page 58 About the doctors Albert Khouri, MD Associate professor of ophthalmology Rutgers New Jersey Medical school Newark, New Jersey Daniel Lee, MD Clinical instructor of ophthalmology Wills Eye Hospital Philadelphia, Pennsylvania Janet Serle, MD Professor emeritus of ophthalmology Icahn School of Medicine at Mount Sinai New York, New York

• Blank Page
• Blank Page (1)